Jiangsu Vcare and Geneseeq Form Strategic Partnership for NTRK Companion Diagnostics
Published Time:
2024-07-02 17:28
Source:
On July 2, 2024, Jiangsu Vcare and Geneseeq signed a strategic cooperation agreement in Nanjing’s Jiangbei New District. The collaboration will focus on the joint development and future commercialization of a companion diagnostic kit for the NTRK inhibitor VC004.
VC004, a second-generation NTRK inhibitor independently developed by Jiangsu Vcare, has demonstrated excellent in vitro and in vivo activity, favorable pharmacokinetic properties, good tolerability, and high response rates in early clinical studies. With no second-generation NTRK inhibitors currently approved in China, VC004 is poised to fill this critical gap.
Jiangsu Vcare: Specializes in the development of innovative drugs and advanced therapies, with deep expertise in R&D and market expansion across oncology, cardiovascular and cerebrovascular diseases, autoimmune disorders, and other therapeutic areas. The company has developed multiple clinical-stage Class I innovative drugs and clinical solutions.
Geneseeq: A leading Chinese precision oncology testing company, Geneseeq possesses advanced high-throughput gene sequencing technologies and extensive experience in diagnostic kit development and regulatory approval. It is the only domestic enterprise with two NGS-based innovative medical device reagent products.
The partnership will leverage the complementary strengths of both parties to accelerate the development and commercialization of VC004’s companion diagnostics, promote the clinical application of NTRK1/2/3 gene fusion detection, and deliver transformative benefits to cancer patients.
Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: “VC004, our self-developed next-generation NTRK inhibitor, is currently in a critical Phase II clinical trial in China. We are honored to partner with our ‘neighbor’ Geneseeq at this pivotal stage. Geneseeq has achieved remarkable success in translating gene sequencing technologies into clinical applications. This collaboration will integrate VC004’s research advancements with Geneseeq’s diagnostic expertise, profoundly addressing unmet clinical needs. We look forward to contributing to medical progress and human health through this partnership.”
Dr. Wang Xiaonan, Co-founder and Chief Technology Officer of Geneseeq, remarked: “As fellow enterprises in Nanjing’s Jiangbei New District, Geneseeq and Jiangsu Vcare have collaborated for years. Both companies prioritize innovation, driven by clinical demand, to achieve high-quality development. I am confident that this strategic alliance will accelerate the efficiency of innovative drug R&D and clinical application, ultimately providing patients with more therapeutic options and greater survival benefits.”
Related News
31
2025
/
10
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Jiangsu Vcare) announced the completion of first patient enrollment in the Phase Ⅱ clinical trial of VC005 Tablets. This independently developed next-generation highly selective JAK1 inhibitor is being evaluated for the oral treatment of non-segmental vitiligo (NSV). The trial aims to assess the efficacy, safety, and PK profile of VC005 Tablets in Chinese adult NSV patients, providing a basis for the selection of dosage in subsequent clinical studies.
View Details
29
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has achieved a major milestone in the Phase Ⅲ clinical trial of VC005 Tablets – the company's independently developed second-generation highly selective JAK1 inhibitor for oral treatment of moderate-to-severe atopic dermatitis (AD) – with the successful completion of full patients enrollment. This multicenter, randomized, double-blind, placebo-controlled pivotal Phase Ⅲ study aims to further validate the efficacy and safety of VC005 Tablets in adult patients with moderate-to-severe AD. The smooth completion of enrollment marks a crucial step forward for this innovative drug towards clinical application.
View Details
15
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the official initiation of the Phase III clinical trial of VC005 Tablets—a self-developed second-generation highly selective JAK1 inhibitor—for the oral treatment of ankylosing spondylitis (AS). This marks the second Phase III clinical trial of VC005 Tablets, following the one for oral treatment of moderate-to-severe atopic dermatitis (AD), signifying that the AS indication has entered the confirmatory clinical research stage.
View Details
12
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) officially initiated the Phase II clinical trial of VC005 Tablets, a second-generation highly selective JAK1 inhibitor independently developed by the company, for a new oral indication – the treatment of non-segmental vitiligo (NSV).
View Details
11
2025
/
08
August 8, 2025 – Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced today that it has entered into an exclusive strategic partnership with Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), for the commercialization rights of Jiangsu Vcare’s innovative product VC005 tablets in mainland China.
View Details
31
2025
/
07
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the completion of full patient enrollment for its Phase II clinical trial of the self-developed, next-generation highly selective JAK1 inhibitor, VC005 topical gel, for the treatment of mild-to-moderate Atopic Dermatitis (AD). This marks a significant milestone in the VC005 gel development program.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn